Skip to main content

Prolonged Air Leak

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Olympus
OlympusPA - Center Valley
1 program
Treatment with HUD IBV Valve SystemN/A1 trial
Active Trials
NCT01166516Completed32Est. Jul 2017
Baxter International
1 program
HemopatchPHASE_31 trial
Active Trials
NCT02491671Completed260Est. Jun 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Baxter InternationalHemopatch
OlympusTreatment with HUD IBV Valve System

Clinical Trials (2)

Total enrollment: 292 patients across 2 trials

Effectiveness Novel Tissue Sealant, Prevention Prolonged Air Leak (PAL) After Lung Resection

Start: Nov 2015Est. completion: Jun 2019260 patients
Phase 3Completed
NCT01166516OlympusTreatment with HUD IBV Valve System

IBV Valve System for the Treatment of Prolonged Air Leak Under HDE H060002 - Post Approval Study

Start: Apr 2010Est. completion: Jul 201732 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.